Table 2.

Deaths due to adverse events while receiving study treatment or within 30 days of all study treatment discontinuation

Adverse event (age)	Therapy at time of AE	Event details
Hemothoraxa (57 years)	RAM, ERL	Event start: day 74 (28 days after last dose of RAM); 5 days after thoracic drainage for pleural empyema
Renal failure (66 years)	ERL	Event start: day 846 (202 days after last dose of RAM); medical history: bilateral hydronephrosis
Pneumonia (74 years)	ERL	Event start: day 483 (454 days after last dose of RAM); medical history: ex-smoker and VATS partial lung resection
Pneumonia bacterial (65 years)	ERL	Event start: day 318 (141 days after last dose of RAM; 5 days after last dose of ERL); medical history: ex-smoker, COPD, recurrent pneumothorax, bulla ligation, lung infections
Encephalitis influenza (59 years)	RAM, ERL	Event start: day 9 (9 days after one dose of RAM); confirmed on microbiological testing
Lymphoma (53 years)	RAM, ERL	Event start: day 80 of treatment; non-biopsy proven: small intestinal lymphoma following abdominal CT scan for melena; discontinued all study treatments because of progressive lung cancer day 92; died day 97

COPD chronic obstructive pulmonary disease, CT computed tomography, ERL erlotinib, RAM ramucirumab, VATS video-assisted thorascopic surgery

^aInvestigator assessed as related to RAM; others not considered related to either study drug